9886 (9886) Fair Value & Analysis

Healthcare · Market cap HK$1.2B

9 9886 9886 · HK

PriceHK$0.9700

Fair ValueHK$1.23

Upside+26.8%

Quality65/100

Watch 9886 for free — get notified when fair value or trend changes. Watch for free

Evidence: Medium Range HK$0.9600 – HK$1.50

Fair value as of: Jul 3, 2026

From 13 valuation models · updated today

Share price +19.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.5100 – HK$1.25 · fair‑value band HK$0.9600 – HK$1.50 · the HK$0.9700 price screens below the HK$1.23 fair value. As of Jul 3, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

9886 (9886) currently trades at HK$0.9700, while our model-based Fair Value estimate is HK$1.23 — implying the stock looks roughly 26.8% undervalued today. We read business quality at 65/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 9886 generated revenue of HK$4.9B at a net margin of -1.0%. Revenue grew 6.7% year over year. It earns a return on equity of -3.1%. The balance sheet holds a net cash position of HK$175M. Fundamentals as of Jul 3, 2026

Key figures & financial health

Revenue (TTM) HK$4.9B

Revenue growth (YoY) +6.7%

Net margin -1.0%

Return on equity -3.1%

Free cash flow HK$123M FY2025

Operating margin 0.3%

More key figures

EPS (TTM) HK$-0.0400

Net cash HK$175M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

9886 reported revenue of HK$4.9B in FY2025 versus HK$3.7B in FY2021, a compound +7.4%/yr. Reported net income was −HK$49.0M in FY2025.

Revenue +7.4%/yr

FY21 HK$3.7B

FY22 HK$4.3B

FY23 HK$4.9B

FY24 HK$4.7B

FY25 HK$4.9B

Net income

FY21 −HK$1.6B

FY22 −HK$2.8B

FY23 −HK$226M

FY24 −HK$376M

FY25 −HK$49.0M

Is 9886 fairly valued? → Check now

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).

Stock	Price	Fair Value	vs Fair Value
Veeva Systems Inc VEEV	$153.16	$183.66	+20%
Pro Medicus Limited PME	A$165.64	A$28.02	-83%
BrightSpring Health Services, Inc BTSG	$60.59	$23.87	-61%
Tempus AI, Inc TEM	$48.61	$12.67	-74%
HealthEquity, Inc HQY	$86.03	$54.47	-37%
M3, Inc MTHRY	$5.21	$7.47	+43%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 9886 (9886) undervalued?

As of Jul 3, 2026, our model estimates a fair value of HK$1.23 versus a price of HK$0.9700 — about +27% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 9886?

Our model-based fair value for 9886 is HK$1.23 (as of Jul 3, 2026), built from audited fundamentals. The current price is HK$0.9700.

What is the quality score of 9886?

9886 has a Quality Score of 65/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 9886 (9886)?

9886 reported trailing-twelve-month revenue of about HK$4.9B (latest available figure, as of Jul 3, 2026).

What is the net profit margin of 9886?

The net profit margin of 9886 is about -1.0%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.